Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4

J Autoimmun. 1998 Feb;11(1):53-62. doi: 10.1006/jaut.1997.0175.

Abstract

The presence of activated CD4(+) T lymphocytes in psoriatic skin plaques suggests an immune-mediated pathogenesis for the disease. Six patients with recalcitrant plaque psoriasis (PASI>12) received a humanized non-depleting monoclonal antibody to CD4 (ORTHOCLONE OKT(R)cdr4a). The antibody was well tolerated. Four weeks from treatment, the mean decrease in PASI score was 46%. In three patients disease remission was prolonged for up to 6 months and, in one case, up to 1 year post-treatment. In all patients, circulating CD4+ T-cell counts remained normal and peripheral OKTcdr4a-coated CD4+ lymphocytes were detected up to 10 days after antibody infusion. These results point to the relevance of CD4+ lymphocytes in psoriasis. They also emphasize that depletion of CD4+ cells is not mandatory to achieve therapeutic effectiveness.

MeSH terms

  • Adult
  • Animals
  • Antibodies, Anti-Idiotypic / biosynthesis
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • CD4 Antigens / blood
  • CD4 Lymphocyte Count
  • CD4-CD8 Ratio
  • CD4-Positive T-Lymphocytes / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Lymphocyte Depletion*
  • Male
  • Mice
  • Monitoring, Immunologic
  • Psoriasis / immunology*
  • Psoriasis / metabolism
  • Psoriasis / pathology
  • Psoriasis / therapy*
  • Recurrence
  • Severity of Illness Index
  • Skin / chemistry
  • Skin / metabolism
  • Skin / pathology
  • T-Lymphocytes / metabolism

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • CD4 Antigens
  • OKT4A monoclonal antibody